Clinical Trial Update: 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated ABT-335 in combination with rosuvastatin versus rosuvastatin alone in adults with dyslipidemia and stage 3 chronic kidney disease; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Dyslipidemia

Drugs mentioned

• ABT-335
• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Dyslipidemia, Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-07-16